BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND MYC, c-Myc, 4609, ENSG00000136997 AND Diagnosis
52 results:

  • 1. Transcription Factors in prostate cancer: Insights for Disease Development and Diagnostic and Therapeutic Approaches.
    Silva KCS; Tambwe N; Mahfouz DH; Wium M; Cacciatore S; Paccez JD; Zerbini LF
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674385
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Molecular complexity of intraductal carcinoma of the prostate.
    Zhu S; Xu N; Zeng H
    Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Treatment-related Neuroendocrine prostate Carcinoma-Diagnostic and Molecular Correlates.
    Gopalan A
    Adv Anat Pathol; 2024 Mar; 31(2):70-79. PubMed ID: 38223983
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Optical genome mapping reveals balanced and unbalanced genetic changes associated with tumor-forming potential in an early-stage prostate cancer epithelial subline (M2205).
    Paulraj P; Barrie E; Jackson-Cook C
    Mol Genet Genomic Med; 2024 Jan; 12(1):e2307. PubMed ID: 37902189
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
    Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
    Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. The role of NFATc1 in the progression and metastasis of prostate cancer: A review on the molecular mechanisms and signaling pathways.
    Hasani S; Fathabadi F; Saeidi S; Mohajernoei P; Hesari Z
    Cell Biol Int; 2023 Dec; 47(12):1895-1904. PubMed ID: 37814550
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Potent carotenoid astaxanthin expands the anti-cancer activity of cisplatin in human prostate cancer cells.
    Erzurumlu Y; Catakli D; Dogan HK
    J Nat Med; 2023 Jun; 77(3):572-583. PubMed ID: 37130999
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
    Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
    Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
    Bray AW; Duan R; Malalur P; Drusbosky LM; Gourdin TS; Hill EG; Lilly MB
    Prostate; 2022 Sep; 82(13):1264-1272. PubMed ID: 35766303
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Identification of Potential Key Genes in prostate cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods.
    Khan MM; Mohsen MT; Malik MZ; Bagabir SA; Alkhanani MF; Haque S; Serajuddin M; Bharadwaj M
    Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456461
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Roles of myc-associated zinc finger protein in malignant tumors.
    Zheng C; Wu H; Jin S; Li D; Tan S; Zhu X
    Asia Pac J Clin Oncol; 2022 Dec; 18(6):506-514. PubMed ID: 35098656
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
    Yamoah K; Asamoah FA; Abrahams AOD; Awasthi S; Mensah JE; Dhillon J; Mahal BA; Gueye SM; Jalloh M; Farahani SJ; Lal P; Rebbeck TR; Yarney J
    Prostate; 2021 Dec; 81(16):1402-1410. PubMed ID: 34529278
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. The 27th Annual prostate cancer Foundation Scientific Retreat Report.
    Miyahira AK; Soule HR
    Prostate; 2021 Nov; 81(15):1107-1124. PubMed ID: 34469608
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Interplay between SOX9 transcription factor and microRNAs in cancer.
    Ashrafizadeh M; Zarrabi A; Orouei S; Zabolian A; Saleki H; Azami N; Bejandi AK; Mirzaei S; Janaghard MN; Hushmandi K; Nabavi N; Baradaran B; Kumar AP; Makvandi P; Samarghandian S; Khan H; Hamblin MR
    Int J Biol Macromol; 2021 Jul; 183():681-694. PubMed ID: 33957202
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Identifying the role of apolipoprotein A-I in prostate cancer.
    Wang J; Xu LF; Liu C; Huang T; Liang CZ; Fan YD
    Asian J Androl; 2021; 23(4):400-408. PubMed ID: 33586698
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins.
    Noé V; Aubets E; Félix AJ; Ciudad CJ
    Biochem Pharmacol; 2021 Jul; 189():114371. PubMed ID: 33338475
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. MicroRNA determinants of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.
    Bhagirath D; Liston M; Patel N; Akoto T; Lui B; Yang TL; To DM; Majid S; Dahiya R; Tabatabai ZL; Saini S
    Oncogene; 2020 Dec; 39(49):7209-7223. PubMed ID: 33037409
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Feasibility and performance of a novel probe panel to detect somatic DNA copy number alterations in clinical specimens for predicting prostate cancer progression.
    Liu W; Hou J; Petkewicz J; Na R; Wang CH; Sun J; Gallagher J; Bogachkov YY; Swenson L; Regner M; Resurreccion WK; Isaacs WB; Brendler CB; Crawford S; Zheng SL; Helfand BT; Xu J
    Prostate; 2020 Oct; 80(14):1253-1262. PubMed ID: 32803894
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Androgen receptor with short polyglutamine tract preferably enhances Wnt/β-catenin-mediated prostatic tumorigenesis.
    He Y; Mi J; Olson A; Aldahl J; Hooker E; Yu EJ; Le V; Lee DH; Kim WK; Robins DM; Geradts J; Sun Z
    Oncogene; 2020 Apr; 39(16):3276-3291. PubMed ID: 32089544
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. MicroRNAs as Diagnostic, Prognostic, and Therapeutic Biomarkers in prostate cancer.
    Aghdam AM; Amiri A; Salarinia R; Masoudifar A; Ghasemi F; Mirzaei H
    Crit Rev Eukaryot Gene Expr; 2019; 29(2):127-139. PubMed ID: 31679268
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.